上海科技大学知识管理系统

本发明属于基因工程领域，涉及基因Sgk1在诊断肝癌肺转移及开发靶向药物中的应用。基因Sgk1的缺失可以使肝癌细胞获得抵抗T细胞免疫进而实施肺转移的能力，Sgk1缺失造成的肺转移瘤可以被免疫检查点(PD‑1, LAG‑3)阻断剂所抑制，Sgk1在原发瘤中低表达的病人更容易发生手术后肝外转移，因此，本发明提供了一种预测肝癌转移和预后的生物标志物Sgk1，并揭示了提高癌症细胞Sgk1的表达水平会抑制肝癌的肝外转移。

The invention belongs to the field of gene engineering, and relates to application of gene Sgk1 in diagnosis of lung metastasis of liver cancer and development of targeted drugs. Due to deletion of the gene Sgk1, liver cancer cells can obtain the ability to resist T cell immunity so as to perform lung metastasis; a lung metastasis tumour due to deletion of Sgk1 can be inhibited by an immune checkpoint (PD-1, LAG-3) blocker; a patient with low expression of Sgk1 in primary tumour is more likely to have extrahepatic metastasis after surgery; and thus, the invention provides a biomarker Sgk1 forpredicting metastasis and prognosis of liver cancer, and discloses that extrahepatic metastasis of liver cancer can be inhibited by increasing the Sgk1 expression level of cancer cells.